102 related articles for article (PubMed ID: 7898711)
21. Serum neopterin after lung transplantation.
Humbert M; Delattre RM; Cerrina J; Dartevelle P; Simonneau G; Emilie D
Chest; 1993 Feb; 103(2):449-54. PubMed ID: 8432135
[TBL] [Abstract][Full Text] [Related]
22. Praziquantel (pyrazinoisoquinolone) in active cerebral cysticercosis.
van Dellen JR; McKeown CP
Neurosurgery; 1988 Jan; 22(1 Pt 1):92-6. PubMed ID: 3344093
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of the therapeutic efficacy of praziquantel against human cysticercosis.
Rim HJ; Joo KH
Acta Leiden; 1989; 57(2):235-45. PubMed ID: 2489002
[TBL] [Abstract][Full Text] [Related]
24. Therapy of parenchymal brain cysticercosis with praziquantel.
Sotelo J; Escobedo F; Rodriguez-Carbajal J; Torres B; Rubio-Donnadieu F
N Engl J Med; 1984 Apr; 310(16):1001-7. PubMed ID: 6708975
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of neurocysticercosis with low-dose praziquantel.
Pun KK; Wong WT
Trop Geogr Med; 1984 Sep; 36(3):303-4. PubMed ID: 6506211
[TBL] [Abstract][Full Text] [Related]
26. [CT follow-up of neurocysticercosis treated with praziquantel].
Schwartz A; Aulich A; Hammer B
Radiologe; 1987 May; 27(5):237-42. PubMed ID: 3615856
[TBL] [Abstract][Full Text] [Related]
27. Re-infection in human schistosomiasis mansoni: a prospective field study 18 months after praziquantel therapy.
Zwingenberger K; Harms G; Poggensee U; Steiner A; Müller O; Feldmeier H
Ann Trop Med Parasitol; 1990 Oct; 84(5):457-65. PubMed ID: 2124097
[TBL] [Abstract][Full Text] [Related]
28. Identification of Taenia solium antigens in cerebrospinal fluid and larval antigens from patients with neurocysticercosis.
Estrada JJ; Estrada JA; Kuhn RE
Am J Trop Med Hyg; 1989 Jul; 41(1):50-5. PubMed ID: 2764228
[TBL] [Abstract][Full Text] [Related]
29. Clinical value of soluble interleukin-2 receptor in infectious complications.
Iwagaki H; Hizuta A; Iwadou H; Perdomo JA; Tanaka N; Orita K
Acta Med Okayama; 1994 Aug; 48(4):225-6. PubMed ID: 7817778
[TBL] [Abstract][Full Text] [Related]
30. Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle.
Proaño JV; Madrazo I; García L; García-Torres E; Correa D
J Neurosurg; 1997 Jul; 87(1):29-33. PubMed ID: 9202261
[TBL] [Abstract][Full Text] [Related]
31. Early CT reevaluation after empiric praziquantel therapy in neurocysticercosis.
Rawlings D; Ferriero DM; Messing RO
Neurology; 1989 May; 39(5):739-41. PubMed ID: 2710366
[TBL] [Abstract][Full Text] [Related]
32. Neurocysticercosis treated with praziquantel. Long-term follow-up of a case.
Mancuso P; Chiaramonte I; Tropea R
J Neurosurg Sci; 1991; 35(3):157-60. PubMed ID: 1774596
[TBL] [Abstract][Full Text] [Related]
33. Serum concentrations of circulating endogenous granulocyte-macrophage colony-stimulating factor in HIV-1-seropositive injecting drug users.
Herold M; Meise U; Günther V; Rössler H; Zangerle R
Presse Med; 1994 Dec; 23(40):1854-8. PubMed ID: 7899316
[TBL] [Abstract][Full Text] [Related]
34. Long-term results of praziquantel therapy in neurocysticercosis.
Robles C; Sedano AM; Vargas-Tentori N; Galindo-Virgen S
J Neurosurg; 1987 Mar; 66(3):359-63. PubMed ID: 3819831
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of albendazole and praziquantel in the treatment of cerebral cysticercosis.
Cruz M; Cruz I; Horton J
Southeast Asian J Trop Med Public Health; 1991 Dec; 22 Suppl():279-83. PubMed ID: 1822906
[TBL] [Abstract][Full Text] [Related]
36. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
Lim KL; Jones AC; Brown NS; Powell RJ
Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
[TBL] [Abstract][Full Text] [Related]
37. Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab.
ter Meulen CG; Göertz JH; Klasen IS; Verweij CM; Hilbrands LB; Wetzels JF; Hoitsma AJ
Kidney Int; 2003 Aug; 64(2):697-703. PubMed ID: 12846768
[TBL] [Abstract][Full Text] [Related]
38. Aspirin reduces serum anti-melanocyte antibodies and soluble interleukin-2 receptors in vitiligo patients.
Zailaie MZ
Saudi Med J; 2005 Jul; 26(7):1085-91. PubMed ID: 16047057
[TBL] [Abstract][Full Text] [Related]
39. Albendazole versus praziquantel in the treatment of cerebral cysticercosis: clinical evaluation.
Cruz M; Cruz I; Horton J
Trans R Soc Trop Med Hyg; 1991; 85(2):244-7. PubMed ID: 1887483
[TBL] [Abstract][Full Text] [Related]
40. A study on the culture medium antigens of Cystcercus cellulosae for detecting antibodies of cysticercosis by means of ABC-ELISA.
Guo H; Zhao ZF; Shi DZ
Southeast Asian J Trop Med Public Health; 1997; 28 Suppl 1():125-7. PubMed ID: 9656362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
